With there being a concern that mastectomy is excessively used as a remedy for breast cancer, a survey of practically two,000 women indicates that breast-conserving surgery was attempted as the initial therapy for about 75 percent of those surveyed, according to a study inside the October 14 issue of JAMA, a theme issue on surgical care.
Monica Morrow, M.D., of Memorial Sloan-Kettering Cancer Center, New York, presented the findings of the study at a JAMA media briefing in Chicago.
“Concerns about excessive use of mastectomy for patients with breast cancer have been raised for a lot more than 2 decades. Rates of breast-conserving surgery (BCS) have been employed by some as a high quality measure. Regardless of a marked increase in BCS, concerns persist that females with breast cancer are getting overtreated with mastectomy,” based on background data inside the post.
Dr. Morrow and colleagues conducted a study to determine the factors girls undergo initial mastectomy for therapy of breast cancer along with the frequency of mastectomy right after BCS is attempted. The study consisted of a survey of girls age 20 to 79 years with intraductal or stage I and II breast cancer diagnosed in between June 2005 and February 2007 and reported to the National Cancer Institute’s Surveillance, Epidemiology, and End Outcomes registries for the metropolitan locations of Los Angeles and Detroit. The final survey sample included 1,984 female patients (502 Latinas, 529 blacks, and 953 non-Hispanic white or other).
The researchers discovered that of the patient population, 75.four percent had BCS as an initial surgical therapy; 23 percent had initial mastectomy; 13.four percent received initial mastectomy based on surgeon recommendation; 8.8 percent received initial mastectomy when the initial surgeon didn’t recommend 1 process more than one more or recommended BCS; and 8.8 percent received mastectomy soon after unsuccessful attempts at BCS.
Of the 1,984 patients, 19.1 percent sought a second opinion about surgical options prior to remedy. “This was a lot more widespread for women with a higher education level and for those advised to undergo mastectomy (33.four percent) vs. those advised to have BCS (15.6 percent) or those that did not obtain a recommendation for 1 process over an additional (21.two percent),” the authors write.
They also found that 11.9 percent of patients who received an initial BCS recommendation received a second opinion for mastectomy; 12.1 percent of the patients who consulted a second surgeon received a discordant opinion. Among the 1,459 females for whom BCS was attempted, additional surgery was required in 37.9 percent of patients. Mastectomy was most widespread in patients with stage II cancer.
“The results of this study suggest that most surgeons in two large, diverse urban regions appropriately recommended local therapy options for patients with breast cancer. The majority of women who received a surgeon recommendation for initial mastectomy reported a clinical contraindication to breast conservation,” the authors write.
“Our outcomes also suggest that patient preferences may possibly play an essential role in shaping the pattern of surgical treatment for breast cancer. One-third of patients appear to choose mastectomy as initial remedy when not given a specific recommendation for BCS or mastectomy by their surgeon, accounting for about one-quarter of total mastectomy use. Patients may possibly prefer mastectomy for peace of mind or to avoid radiation.”
“In conclusion, findings of this survey of girls with breast cancer demonstrate that the etiology [cause] of existing mastectomy rates is multifactorial, but that BCS is recommended by surgeons and attempted in a majority of patients,” the researchers write. “Our findings suggest that a combined approach of education for patients and well being care professionals targeting specific areas may possibly increase decision creating.”
JAMA. 2009;302[14]:1551-1556.
Source Journal of the American Medical Association
Phyton Biotech GmbH, a globe leader in plant cell culture technology, reports that the European Patent Office has announced its intention to grant a European patent to Phyton covering methods of producing taxanes such as paclitaxel.
Paclitaxel, the active ingredient in Bristol-Myers Squibb’s TAXOL?, is beneficial in the treatment of breast, ovarian, lung, and other forms of cancer. Phyton produces paclitaxel broth for a key pharmaceutical firm under a long-term supply agreement. Phyton’s paclitaxel is produced in plant cell culture by a proprietary method developed as an alternative to harvesting tree bark or plantations as a taxane source.
The patent will broadly cover methods for producing commercial levels of taxanes such as paclitaxel by cultivating cells of Taxus chinensis, a species of the yew tree, in plant cell culture containing effective concentrations of silver and an auxin. The patent, which will expand Phyton’s existing IP portfolio, protects Phyton’s European production of paclitaxel via its plant cell culture processes. Also, the patent confirms Phyton’s exclusive rights to produce paclitaxel pursuant to this process and might be asserted against any third party utilizing the patented process in Europe, or importing merchandise created by the patented process into Europe.
Dr. Harald Heckenm???1ller, General Manager of Phyton Biotech GmbH, commented: “We are pleased that the European Patent Workplace recognizes Phyton’s innovative approach for producing commercial levels of anticancer compounds such as paclitaxel. The announced intention of the European Patent Office will further enhance our existing IP portfolio and affirms our position as the only commercial source in Europe for taxanes such as paclitaxel via plant cell fermentation. We are determined to effectively defend this position.”
Women who developed new-onset breast tenderness right after beginning estrogen plus progestin hormone replacement therapy were at substantially higher risk for creating breast cancer than girls on the combination therapy who didn’t experience such tenderness, based on a new UCLA study.
The investigation, published inside the Oct. 12 issue of the Archives of Internal Medicine, is based on information from more than 16,000 participants within the Women’s Well being Initiative estrogen-plus- progestin clinical trial. This trial was abruptly halted in July 2002 when researchers identified that healthy menopausal females on the combination therapy had an elevated danger for invasive breast cancer.
Researchers do not know why breast tenderness indicates increased cancer danger amongst girls on the combination therapy, said the new study’s lead researcher, Dr. Carolyn J. Crandall, a clinical professor of general internal medicine and wellness services investigation in the David Geffen School of Medicine at UCLA.
“Is it because the hormone therapy is causing breast-tissue cells to multiply more rapidly, which causes breast tenderness and in the exact same time indicates increased cancer danger? We have to figure out what makes certain ladies a lot more susceptible to developing breast tenderness in the course of hormone therapy than other girls,” Crandall said.
This study compared the every day use of oral conjugated equine estrogens (0.625 mg) plus medroxyprogesterone acetate (2.5 mg), or CEE+MPA, using the everyday use of a placebo pill.
Of the participants within the trial, 8,506 took estrogen plus progestin and 8,102 were given placebos. Participants underwent mammography and clinical breast exams at the start of the trial and annually thereafter. Self-reported breast tenderness was assessed at the beginning of the trial and 1 year later, and invasive breast cancer over the next five.6 years was confirmed by medical record review.
Women on the combination therapy who did not have breast tenderness at the trial’s inception had been identified to have a threefold greater risk of developing tenderness in the one-year mark, compared with participants who had been assigned placebos (36.1 percent vs. 11.8 percent). Amongst the females who did report breast tenderness in the beginning, the danger at one-year was about 1.26 occasions that of their counterparts on placebos.
Of the ladies who reported new-onset breast tenderness, 76.3 percent had been on the combination therapy.
Women within the combination therapy group who did not have breast tenderness at the outset but experienced new-onset tenderness in the initial annual follow-up had a 48 percent greater danger of invasive breast cancer than their counterparts on combination therapy who didn’t have breast tenderness at the first-year follow-up.
“To our knowledge, no prior published studies have addressed no matter whether there’s an association between CEE+MPA-induced new-onset breast tenderness and breast cancer threat,” Crandall said.
The study does have limitations. The information the researchers utilized assessed breast tenderness only annually and thus could have underestimated it. Also, the rates of girls discontinuing the combination therapy and switching from placebos to active therapy were relatively high, although the researchers believe this could have decreased, rather than increased, the observed association among new-onset tenderness and cancer risk. And the results do not apply to other sorts of estrogen or progestin therapy.
Study co-authors had been Rowan Chlebowski of UCLA; Aaron K. Aragaki, Anne McTiernan and Garnet Anderson of the Fred Hutchinson Cancer Investigation Center in Seattle; Susan L. Hendrix of Wayne State University-Hutzel Women’s Hospital in Detroit; Barbara B. Cochrane of the University of Washington; and Lewis H. Kuller and Jane A. Cauley of the University of Pittsburgh.
Grants from the National Institute on Aging as well as the Tarlow-Eisner-Moss Research Endowment of the Iris Cantor-UCLA Women’s Health Center funded Crandall’s investigation. Funding for the Women’s Well being Initiative comes by means of the National Heart, Lung and Blood Institute of the National Institutes of Wellness.
Source: Enrique Rivero University of California – Los Angeles
Clinical experience using the FDA cleared Axxent? Electronic Brachytherapy, eBx(TM), Program from Xoft shows promise for the multi-disciplinary use of the isotope-free cancer treatment platform to deliver intraoperative radiation therapy (IORT). Xoft will showcase a variety of investigational IORT oncology applications in the American College of Surgeons 95th Annual Clinical Congress here in Chicago, October 11-15, 2009.
IORT is actually a radiation therapy technique where a concentrated dose of radiation is delivered to a cancerous tumor site for the duration of surgery right after the tumor is removed. Because the target and standard tissues might be clearly identified during surgery, IORT may enhance targeting accuracy, thereby increasing dose to the target and reducing dose to vital structures. For breast IORT, the shorter treatment time is generally more convenient for patients than the seven-week course of external beam-therapy, and could boost patient compliance.
“We are very pleased with the strong interest from clinicians around the country to investigate multi-disciplinary approaches for use of Electronic Brachytherapy to deliver IORT for breast and other cancers,” said Michael Klein, president and CEO of Xoft. “Currently, we’re supporting studies investigating spine, inter-abdominal and breast applications, and as far more oncologists and surgeons understand this powerful tool, we expect to see studies investigating treatments for pancreatic and other recurring cancers.”
“At Small Firm of Mary Hospital, we have treated a number of patients making use of breast IORT with excellent outcomes. Combined with information from European studies showing comparable results to whole-breast irradiation and other forms of APBI, we think these preliminary results are quite encouraging and deserve the attention of American breast surgeons,” stated Olga Ivanov, M.D., breast surgeon and medical director for Small Firm of Mary’s Comprehensive Breast Wellness Center.
The Xoft eBx Method uses a miniature X-ray source instead of a radioactive isotope to deliver radiation to the breast from within a balloon catheter. The low energy and rapid dose fall-off of the electronic source permit remedy in typical operating rooms, with minimal shielding required. Lightweight and mobile, the system may be moved easily among multiple ORs.
“I think that giving a single fraction of radiation in the time of surgery will be advantageous since it will allow all of the radiation to be delivered before any remaining tumor cells have a chance to grow. It also intensifies the dose to the part of the breast at highest danger for recurrence. My hope is that the availability of IORT will decrease the number of patients who decide to be treated with surgery alone despite the fact that radiation has been shown to be an essential component of remedy and increases overall survival,” stated Adam Dickler, M.D., radiation oncologist at Little Firm of Mary Hospital.
Available for therapy of early stage breast cancer, endometrial cancer, and skin cancer, the Axxent eBx Program is also FDA-cleared for IORT (intra-operative radiation therapy). As a platform technology, the Axxent System is created to deliver non-radioactive therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue. Utilizing a proprietary miniaturized X-ray source and robotic controller, the system might be employed to deliver radiation in minimally shielded therapeutic settings. Therapy may be performed without the need for a shielded room, allowing the radiation oncologist and other medical personnel to be present during remedy delivery which minimizes patient anxiety.
“In breast cancer, we know there is a large segment of patients, often the elderly and girls who live longer distances from radiation centers, who do not comply with their prescribed radiation therapy after lumpectomy or who choose to have a mastectomy instead of pursuing breast conserving therapy. For these tens of thousands of ladies, IORT may possibly an important choice to improve access to therapy together with increase outcomes,” added Klein. “What will be essential whether or not it really is breast or an additional oncology application, is that the treatment is directed using a multi-disciplinary approach, involving specialists in radiation oncology, surgery and pathology.”
About Xoft, Inc.
Xoft develops Electronic Brachytherapy (eBx) systems based upon miniaturized X-ray tube technologies for the practice of radiation oncology in virtually any clinical setting, eliminating the need to have for heavily shielded environments. The Axxent? therapy platform offers a therapeutic dose of radiation directly towards the region at danger with minimal radiation exposure to surrounding healthy tissue and without the complex handling, resource logistics and costs associated with employing radioactive isotopes. Xoft aligns using the Nuclear Regulatory Commission’s (NRC) directive to seek alternatives for radioactive medical isotopes. Commercially accessible for treatment of early stage breast cancer, skin cancer and endometrial and rectal indications, the Axxent Electronic Brachytherapy Program is also cleared for use within the therapy of other cancers or conditions exactly where radiation therapy is indicated.
Axxent is actually a registered trademark and eBx is really a trademark of Xoft, Inc.
Cancer charities will today join Gordon Brown to highlight the lifesaving importance of breast cancer screening.
The NHS breast cancer screening programme at present diagnoses more than 14,000 cases of breast cancer every year and saves around 1,400 lives every year. Even so in 2008 27% of ladies failed to take up their right to breast screening. Figures show that if all females took up their right to screening an extra 600 lives might be saved.
Speaking before a reception at Downing Street to mark Breast Cancer Awareness, the Prime Minister said:
“Through early diagnosis, early treatment and our historic investment in analysis for cures we want to transform cancer care in Britain so that we beat the disease in this generation.
“That is why we have already extended our breast screening programme to a broader age group and that is why today, together with all the breast cancer charities, I am calling for all females to create the important choice to take up their right to breast screening.”
Chief Executive of Cancer Analysis UK Harpal Kumar said:
“Screening saves lives, so it’s extremely worrying to see that the percentage of females going for breast screening is dropping. Mammograms pick up the quite early signs of breast cancer when it’s significantly easier to treat and when treatment is usually successful. This trend need to be reversed. If there were 100 per cent attendance at breast screening, hundreds far more lives might be saved.”
Chief Executive of Breast Cancer Care Samia al Qadhi said:
“From our work around this issue we know that a lot of females, particularly older women and those from black and minority ethnic communities, are less most likely to be aware of the signs and symptoms of breast cancer.
“The importance of early detection, either by reporting a symptom to your GP or through the screening process, can not be underestimated.
“It is vital that girls obtain clear and consistent info on the risks, signs and symptoms of breast cancer and we have been delighted to work using the Department of Wellness in preparing these new key messages.”
Chief Executive of Breakthrough Breast Cancer Jeremy Hughes said: “
“Breakthrough encourages anyone more than 50 to attend NHS Breast Screening appointments as early diagnosis of breast cancer provides the best chance that therapy will be successful.
“It’s also vital that women are breast aware but we know there’s confusion about how you can check your breasts and what to appear for. Breakthrough has developed a simple reminder to assist females be breast aware: show your breasts some TLC – touch and appear for any changes and check anything unusual with your doctor.”
Chief Executive of Breast Cancer Campaign Pamela Goldberg stated: “
“We support the Government’s commitment towards the NHS breast screening programme which we know is an crucial tool in the early detection of breast cancer. We now should build on this success by encouraging all girls, particularly those from hard to reach communities, to attend their screening appointments as early diagnosis saves lives.”
“We welcome the recognition by the Government that study is crucial to beating breast cancer and remain committed to funding groundbreaking study.”
Also today, a single set of key messages on breast cancer, agreed by cancer charities, NHS staff and patient groups are also published today on the NHS Choices web site to ensure females get clear advice.
According to a new study published inside the October issue of the Journal of the American College of Surgeons, though breast-conserving surgery (BCS), typically identified as lumpectomy, is increasingly getting used to treat older girls with nonmetastatic invasive breast cancer, you’ll find still significant socioeconomic and geographic disparities in the use of this type of therapy. For example, females within the Northeast and Pacific West are considerably a lot more most likely to get BCS than those in the South and parts of the Midwest.
In BCS, only a portion of the affected breast is removed, whereas a mastectomy involves removing all of the breast tissue, sometimes along with other nearby tissues. Combined with radiotherapy, BCS is as effective as a mastectomy for remedy of early invasive breast cancer. Yet despite the large body of evidence supporting the efficacy of BCS, studies conducted inside the last two decades reported that much less than half of all surgically treated patients with nonmetastatic invasive disease received BCS.
“Treatment of nonmetastatic invasive breast cancer has improved substantially more than the past numerous decades, but we continue to fall short of the goal to treat each and every woman with the highest high quality care,” stated Grace L. Smith, MD, PhD, Postdoctoral Fellow, Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center. “Our study suggests that barriers exist that might prevent a lot of girls with breast cancer – specifically those in poorer areas, locations with low education levels, rural communities and counties with few radiation oncologists – from getting supplied each remedy alternative that really should be available to them.”
Using a national Medicare database, researchers identified women age 65 years and older who were surgically treated in 2003 for invasive breast cancer. Claims codes identified demographic, treatment and geographic region covariates. The 2003 Area Resource File provided socioeconomic data.
Of 56,725 ladies in the database, 59 percent had been treated with BCS versus 41 percent with mastectomy. BCS was more widely employed in females who had been younger than 70 years (odds ratio [OR], 1.37; p<0.001) and had lymph node-negative disease (OR, 1.60; p<0.001). The results showed that socioeconomic and demographic factors influenced the type of surgical procedure, with BCS more prevalent in areas with low poverty (OR, 1.05; p=0.03), high education (OR, 1.13; p<0.001) or a high density of radiation oncologists (OR, 1.30; p=0.01), and in metropolitan areas (OR, 1.20; p<0.001). Results also revealed disparities between geographic regions. Patients in the Northeast and Pacific West were the most likely to undergo BCS (around 79 percent and 71 percent, respectively), while patients in the South and portions of the Midwest were the least likely (57 to 59 percent and 58 percent, respectively).
Women with increased levels of M???1llerian inhibiting substance (MIS), best recognized for regulating in utero sexual differentiation in boys, might be at a higher risk for breast cancer, according to a new study published online October 9 inside the Journal of the National Cancer Institute .
To determine whether or not MIS levels were related to breast cancer danger, Joanne F. Dorgan, Ph.D., MPH, of the Fox Chase Cancer Center in Philadelphia, and colleagues conducted a prospective case-control study of 309 participants who had been registered in the Columbia, Missouri Serum Bank. Blood samples had been donated by ladies with in situ or invasive breast cancer who, in the time of donation, had been totally free of cancer. Every of 105 breast cancer patients was matched to two control subjects. MIS was measured in serum using an enzyme-linked immunosorbent assay.
Researchers located that growing MIS serum concentrations were associated with increased breast cancer threat in this population.
“Additional analysis is necessary, including confirmatory epidemiological studies on the association of serum MIS with breast cancer and studies aimed at identifying the biological mechanism underlying the association,” the authors write.
Source: Steve Graff Journal of the National Cancer Institute
Locally advanced breast cancer patients who received exactly the same class of neoadjuvant chemotherapy were found to have no evidence of disease in the time of their surgery, or achieved pathological complete response, in the exact same rate regardless of race, based on researchers at the University of Texas M. D. Anderson Cancer Center.
The study, presented in a poster discussion session at the 2009 Breast Cancer Symposium in San Francisco, may be the largest in a homogenous group of breast cancer patients evaluating pathological complete response (pCR) based on race. Only 1 other study, also conducted at M. D. Anderson but limited to triple negative breast cancer patients (estrogen and progesterone receptor negative, HER2 negative), has analyzed the relationship among the two.
“Our findings confirm pathological complete response can be a strong prognostic indicator as well as a surrogate for great survival, in spite of a patient’s race, and that it’s vital we continue to strive towards achieving this milestone for all women with breast cancer,” stated Mariana Chavez Mac Gregor, M.D., a medical oncology fellow at M. D. Anderson. “The study also mandates that we continue to study the differences across races in breast cancer.”
Racial disparities in breast cancer are known: the American Cancer Society (ACS) estimates that 19,540 blacks and 14,200 Hispanics will be diagnosed with the disease in 2009. While the overall incidence rate is 10 percent lower in blacks than whites, in 2001-2005, they had a 37 percent greater death rate. ACS also reports that overall breast cancer mortality rates are lower in Hispanic girls than white females.
Understanding the reasons for such disparities – be it access to care and screening, biological differences in tumors and/or breast cancer subtypes – will be the focus of ongoing investigation efforts across the cancer community, explained Chavez Mac Gregor, the study’s 1st author.
“While these disparities are known, we also comprehend that breast cancer patients who achieve pathological complete response have far better outcomes,” stated Chavez-Mac Gregor. “What we didn’t comprehend till now was if pathological complete response rates had any relationship with race. If a specific ethnic group had a greater or worse response rate, maybe we could then determine which groups might be in require of additional and /or improved therapies.”
Using the M. D. Anderson Breast Medical Oncology database, the retrospective study identified two,074 patients diagnosed with Stages II and III breast cancer and treated in the institution in between 1994 and 2008. Of the patients, 1,334 (64.three percent) had been white, 302 (14.6 percent) black, 316 (15.2 percent) Hispanic, and 122 (5.9 percent) had been classified as “other” race groups. The median age of the ladies was 50. All received neoadjuvant anthracycline- and taxane-based chemotherapy; receiving similar class of therapy was an critical component inside the design of the study, said Chavez Mac Gregor.
At the time of surgery, the researchers discovered no distinction of statistical significance in pCR rates amongst racial groups: 12.three percent in whites; 12.5 percent in blacks; 14.24 percent in Hispanics; 11.5 percent in other.
Among all patients, at a median follow-up of 30 months, there were 438 recurrences and 327 deaths. The 5 year unadjusted recurrence-free (RFS) and overall survival (OS) rates were: 71 percent and 79 percent in whites; 60 percent and 57 percent in blacks; 76 percent and 79 percent in Hispanics; and 75 percent and 84 percent in “other,” respectively. Lack of achieving pCR, HER2-positive and triple-negative subtypes, lymph node involvement had been all discovered to be independent predictors of worse RFS and OS.
In further analysis, the study reconfirmed what had been noted in literature – despite the fact that not statistically significant, blacks tended to have poorer outcomes, whilst Hispanics had improved outcomes compared to whites, said Chavez Mac Gregor.
The study is not without limitations, she noted: in design, it was each retrospective along with a single-institution study, and race was self-reported. Furthermore, the analysis focus was until the time of surgery, with less attention towards patients’ experience post-surgery, such as compliance to hormone therapies or other adjuvant remedies, other than RFS and OS.
In exactly the same cohort of patients, Chavez Mac Gregor plans further analysis of patients who did not achieve pCR to much better realize why they might not have reached this milestone.
The study was funded by grants from the National Cancer Institute and Susan G. Komen for the Remedy.
In addition to Chavez Mac Gregor, M. D. Anderson authors on the study contain: Gabriel N. Hortobagyi, M.D.; Ana Maria Gonzalez-Angulo, M.D., the study’s senior author; Jennifer Litton, M.D.; Vicente Valero, M.D.; and Huiqin Chen, all of the Department of Breast Medical Oncology; Funda Meric-Bernstam, M.D., Department of Surgery; and Melissa Bondy, Ph.D., Department of Epidemiology. Other authors consist of: Clifford A. Hudis, M.D., Memorial Sloan Kettering; and Antonio C. Wolff, M.D., The Sidney Kimmel Comprehensive Cancer Center.
About M. D. Anderson
The University of Texas M. D. Anderson Cancer Center in Houston ranks as 1 of the world’s most respected centers focused on cancer patient care, study, education and prevention. M. D. Anderson is one of only 40 comprehensive cancer centers designated by the National Cancer Institute. For six of the past eight years, such as 2009, M. D. Anderson has ranked No. 1 in cancer care in “America’s Best Hospitals,” a survey published annually in U.S. News & Globe Report.
Source: University of Texas M. D. Anderson Cancer Center
Article Opinions:1 posts Women having a deleterious gene mutation are diagnosed with breast cancer six years earlier than relatives of the previous generation who also had the illness and/or ovarian cancer, according to new analysis from The University of Texas M. D. Anderson Cancer Center.
The findings, presented in a poster session at the 2009 Breast Cancer Symposium, could have an impact on how girls at highest risk for the illness are counseled and even screened inside the future, explained Jennifer Litton, M.D., assistant professor in M. D. Anderson’s Department of Breast Medical Oncology.
“In our practice, we’ve noticed that girls having a identified deleterious BRCA gene mutation are being diagnosed earlier with the disease than their moms or aunts,” said Litton, M.D., the study’s very first author. “With this study, we looked at ladies who had been each treated and had their BRCA testing at M. D. Anderson to determine if what we had been seeing anecdotally was consistent scientifically.”
It’s estimated that five to 10 percent of all breast cancers are related to either the BRCA1 or two mutation, both of which are associated with an increased threat for breast and ovarian cancers. Based on the American Cancer Society (ACS), females with BRCA1 or 2 have a 60 percent lifetime danger of developing breast cancer, compared to a 12 percent risk for girls inside the general population.
Given their greater danger, females with identified BRCA mutations and/or whose mothers and/or aunts from either side of the household have the mutation are screened beginning at age 25. In 2007, as a complement to mammography, ACS guidelines added Magnetic Resonance Imaging (MRI) in the surveillance of these girls at highest threat, as MRI is thought to catch smaller tumors even earlier. Consideration of prophylactic mastectomies is also a component of their surveillance, said Litton.
“Currently, BRCA positive ladies are counseled that they won’t must worry about breast cancer till a certain age. Nonetheless, our findings show that we may actually begin seeing the disease even earlier in future generations. We must make changes accordingly in order to best advise and care for these females at greatest risk,” Litton said.
For the retrospective study, the researchers identified 132 BRCA positive women with breast cancer who participated in a high-risk protocol via M. D. Anderson’s Clinical Cancer Genetics Plan among 2003 and 2009. Reviewing each woman’s pedigree (loved ones tree), 107 were identified to have a female loved ones member inside the previous generation who also had a BRCA-related cancer, either breast or ovarian. Age at diagnosis, location of mutation and birth year had been recorded in each the older (gen1) and younger (gen2) ladies.
The study identified that in gen2, the median age of diagnosis was 42, compared to age 47 in gen1. In comparing generations within a household, the median distinction was six years. Comparing decades of birth in all born soon after 1950, gen2 had been diagnosed earlier than gen1. When stratified by BRCA1 or 2 mutation, the median age of diagnosis in BRCA1 and BRCA2 positive gen2 women was 42 and 44, respectively, and 43 and 50, respectively in BRCA1 positive and BRCA2 positive gen1 females.
“These findings are certainly concerning and could have implications on the screening and genetic counseling of these females,” Litton said. “In BRCA positive girls with breast cancer, we actually might be seeing true anticipation the phenotype or cancer coming out earlier per generation. This suggests a lot more than the mutation could be involved, perhaps lifestyle and environmental elements are also coming into play.”
The research reconfirms that females with BRCA mutations ought to continue to be screened per the guidelines – mammography, MRI and consideration of prophylactic surgeries but perhaps with increased suspicion and even at an earlier age, stated Litton, who notes that the addition of MRI screening may possibly account for a number of the change in diagnosis observed inside the study.
Further analysis is necessary given the relatively small number of females inside the cohort along with the possibility of recall bias, as the gen2 ladies had been offering their family histories, Litton explained. As follow up study, Litton plans to appear into biological basis for potential earlier diagnosis.
The study was funded by the Nellie B. Connally Breast Cancer Investigation Fund
In addition to Litton, other authors on the all-M. D. Anderson study include: Gabriel Hortobagyi, M.D.; Banu Arun, M.D., the study’s senior author; Kaylene Ready; Angelica Gutierrez Barrera; Huiqin Chen, all of the Department of Breast Medical Oncology; Funda Meric-Bernstam, M.D., Department of Surgery; and Karen Lu, M.D., Department of Gynecologic Oncology.
About M. D. Anderson
The University of Texas M. D. Anderson Cancer Center in Houston ranks as 1 of the world’s most respected centers focused on cancer patient care, investigation, education and prevention. M. D. Anderson is 1 of only 40 comprehensive cancer centers designated by the National Cancer Institute. For six of the past eight years, such as 2009, M. D. Anderson has ranked No. 1 in cancer care in “America’s Best Hospitals,” a survey published annually in U.S. News & World Report.
Source: University of Texas M. D. Anderson Cancer Center
Researchers from Boston University School of Medicine (BUSM) have identified a tool, the “Getting-Out-of-Bed (GoB) measure” to assess motivation and life outlook in older adults. The study, which appears within the October issue of the Journal of Psychosocial Oncology, shows that the tool has the potential to be an easy-to-use measure to bolster motivation and thus, boost wellness behaviors and outcomes in the growing population of older adults.
The demographics of aging inside the United States continues to change dramatically. In 2006, 37 million Americans, 12 percent of the population had been 65 years or older. By 2030, those 65 years and older are projected to number 71.five million representing nearly 20 percent of the US population. Furthermore, in between 1992 and 2004 average inflation-adjusted wellness care costs for older Americans increased from $8,644 to $13,052 and are expected to continue to rise considerably. Based on the researchers, such numbers underscore the importance of understanding frequent diseases and well being behaviors of older adults, due to the fact many conditions can be prevented and/or modified with behavioral interventions.
“Motivation and life outlook play an critical part in an older adult’s capacity to recover from illness or disabling events and to maintain and/or adopt health-promoting behaviors,” stated lead author Kerri Clough-Gorr, DSc, MPH, from the Section of Geriatrics at BUSM.
The researchers conducted telephone interviews on a sample of 660 ladies with breast cancer from four geographic regions of the country at 3 and six months intervals. Motivation and life outlook was assessed employing GoB questions. Girls with GoB scores ?Y50 (representing higher motivation) at baseline had been statistically drastically much more likely at 6 months to have very good health-related good quality of life, good self-perceived health and report regular exercise than those with scores <50, indicating good predictive ability.
“The capability to identify patients with low motivation establishes an opportunity for well being care providers to develop and implement interventions to improve older adults’ motivation and to help them attain and maintain a higher top quality of well being and life. The GoB could assist target adequate interventions to bolster motivation and thus enhance wellness behaviors and outcomes in older adults,” added Clough-Gorr.
This study was supported by grants from the National Cancer Institute.
Source: Gina Digravio Boston University Medical Center